Codexis Partners with Nitto Denko to Enhance Oligonucleotide Therapeutics Manufacturing

Codexis Partners with Nitto Denko Avecia to Advance Oligonucleotide Therapeutics

Codexis, Inc., a leader in enzymatic solutions for therapeutic manufacturing, establishes an evaluation agreement with Nitto Denko Avecia, Inc., a well-respected contract development and manufacturing organization (CDMO) specializing in oligonucleotide therapeutics. This collaboration focuses on assessing Codexis' ECO Synthesis® Manufacturing Platform, a groundbreaking approach designed to enhance the scalability and sustainability of oligonucleotide synthesis. By leveraging a flexible, enzyme-catalyzed methodology, the ECO Synthesis platform aims to surpass the limitations of traditional solid-phase synthesis methods, marking a significant innovation in the field.

Stephen Dilly, Chairman and CEO of Codexis, expresses optimism about the partnership, recognizing its potential to extend the reach of their innovative technology through collaboration with esteemed CDMOs. This initiative is particularly relevant as the demand for scalable and sustainable solutions in therapeutic small interfering RNA (siRNA) manufacturing continues to grow. By aligning with Nitto Denko Avecia, Codexis positions itself at the forefront of a critical development in the biopharmaceutical industry, where the efficiency and quality of manufacturing processes are paramount to meeting the evolving needs of healthcare.

Tammy Cooper, President of Nitto Denko Avecia, echoes this sentiment, emphasizing the company's dedication to pioneering next-generation manufacturing technologies that enhance both efficiency and quality in therapeutic development. With a proven history of manufacturing over 1,500 oligonucleotide sequences for various applications, Nitto Denko Avecia's expertise complements Codexis' innovative platform, creating a formidable alliance aimed at delivering high-quality therapeutic solutions. This partnership is not only a strategic move for both companies but also a vital step toward advancing the capabilities of oligonucleotide therapeutics on a global scale.

In addition to the agreement with Nitto Denko Avecia, Codexis continues to highlight its commitment to redefining therapeutic development and manufacturing. By consistently outperforming traditional methods, the company aims to be a long-term partner in driving progress across the healthcare ecosystem. As the biopharmaceutical landscape evolves, partnerships like this one will play a crucial role in shaping the future of therapeutic manufacturing.

This collaboration signifies a pivotal moment in the journey toward effective therapeutic solutions, promising advancements that can meet the growing demands of partners and patients worldwide. Codexis, through its innovative approach and strategic alliances, demonstrates a proactive stance in addressing the challenges faced within the healthcare sector.